期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 147, 期 3, 页码 814-826出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2020.10.022
关键词
Autoimmune disease; baricitinib; inflammatory disease; JAK inhibitor; Janus kinase inhibitor; JAK-STAT; ruxolitinib; tofaci-tinib; upadacitinib; cytokine
资金
- Dermatology Foundation
- Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research
Autoimmune and inflammatory diseases are commonly treated by targeting dysregulated cytokine activity, with the emergence of JAK inhibitors offering a new approach that simultaneously blocks multiple pathogenic cytokines. These small molecule inhibitors show promising results and are becoming increasingly important in the treatment of various autoimmune and inflammatory disorders.
Autoimmune and inflammatory diseases are common and diverse, and they can affect nearly any organ system. Much of the pathogenesis of these diseases is related to dysregulated cytokine activity. Historically, autoimmune and inflammatory diseases have been treated with medications that nonspecifically suppress the immune system. mAbs that block the action of pathogenic cytokines emerged 2 decades ago and have become widely useful. More recently, agents that simultaneously block multiple pathogenic cytokines via inhibition of the downstream Janus kinase (JAK)? signal transducer and activator of transcription pathway have emerged and are becoming increasingly important. These small molecule inhibitors, collectively termed JAK inhibitors, are US Food and Drug Administration?approved in a few autoimmune/ inflammatory disorders and are being evaluated in many others. Here, we review the biology of the JAK?signal transducer and activator of transcription pathway and the use of JAK inhibitors to treat autoimmune and inflammatory diseases across medical subspecialties. (J Allergy Clin Immunol 2021;147:814-26.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据